OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
At the 2024 SGO Annual Meeting on Women's Cancer, Herzog presented results from a subgroup analysis of the phase 2 AMPECT trial. Nab-sirolimus is the first and only FDA-approved treatment for advanced PEComa.
"The median time to response was extremely fast, about 1.4 months, and the duration of response was a little over 36 months," Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center, told Targeted Oncology. "It is important to remember these responses occur often rapidly, and they are quite durable."
Watch the Targeted Oncology video.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
UC political science experts explain implications of Midterm elections
November 5, 2026
Faculty from UC's School of Public and International Affairs helped local and national media outlets understand the issues surrounding the Midterm election results.
Shawn Brown named College of Medicine's senior associate dean for strategic planning, integration and institutional performance
November 5, 2026
Shawn Brown has been named the University of Cincinnati College of Medicine's senior associate dean to lead continuous strategic planning aligned with university and academic health enterprise priorities.
Can teaching more people about science increase public trust?
November 4, 2026
The Center for Public Engagement with Science talks to WVXU's Cincinnati Edition about ways the University of Cincinnati is working to improve science literacy and build public trust in science.